Hold Recommendation?: Abbott Laboratories (ABT)

Tuesday, 17 Apr, 2018

The company has its outstanding shares of 1.82 Billion. In most recent quarter, LT Debt/Equity ratio was listed at 0.88 and Total Debt/Equity ratio was noted at 0.90. This gives investors an idea of how much the security has moved in the a year ago and whether it is trading near the top, middle or bottom of the range. About 132,040 shares traded. It has outperformed by 7.17% the S&P500.

Solaris Asset Management Llc increased its stake in Corning Inc (GLW) by 138.46% based on its latest 2017Q4 regulatory filing with the SEC. Destination Wealth Management sold 9,138 shares as the company's stock rose 5.88% while stock markets declined. The institutional investor held 28,615 shares of the telecommunications equipment company at the end of 2017Q4, valued at $915,000, up from 12,000 at the end of the previous reported quarter. The company has a market cap of $107.39 Billion. The stock increased 0.60% or $0.71 during the last trading session, reaching $119.87. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 12, 2017 and is uptrending. ABT outperformed by 23.30% the S&P500. Its up 0.04, from 0.87 in 2017Q3. Abbott Laboratories (ABT) recently closed with fall of -3.51% to its 20-Day Simple Moving Average.

Several other hedge funds have also added to or reduced their stakes in ABT. Stockholders of record on Friday, April 13th will be given a $0.28 dividend. Groesbeck Inv Mngmt Corp Nj holds 1.22% or 30,381 shares. Benjamin F Edwards & holds 23,951 shares.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Arrowstreet Cap Ltd Partnership invested in 26,800 shares. Primecap Co Ca reported 14.61 million shares. Nuance Invs Lc has 680,231 shares.

Abbott Laboratories (ABT) stock price recognized up trend built on latest movement of 200 SMA with 5.97% during the course of recent market activity. Salem Investment Counselors stated it has 88,464 shares or 0.55% of all its holdings. Cheviot Value Mgmt Ltd Co accumulated 60,332 shares or 1.78% of the stock. Headinvest Limited Liability Company reported 0.2% in Abbott Laboratories (NYSE:ABT). Finally, Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Abbott Laboratories by 1.9% in the third quarter. Beach Investment Management LLC. increased its holdings in shares of Abbott Laboratories by 2,161.4% in the 2nd quarter.

Since October 23, 2017, it had 1 buying transaction, and 19 sales for $28.95 million activity. On Wednesday, February 28 the insider Funck Robert E sold $71,970. Shares of ABT moved downward with change of -3.04% to its 50-day Moving average. Another trade for 29,949 shares valued at $945,178 was sold by Musser Eric S. The insider Pambianchi Christine M sold $29,895. Bracken Sharon J had sold 2,100 shares worth $126,559. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Therefore 72% are positive. Wealthfront Inc.'s holdings in Abbott Laboratories were worth $3,533,000 at the end of the most recent reporting period. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Friday, January 29. Cowen & Co maintained the shares of ABT in report on Wednesday, October 18 with "Buy" rating. ValuEngine raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, March 1st. On Friday, October 9 the stock rating was maintained by RBC Capital Markets with "Outperform". The companyÂ's Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.219.85 is the P/E ratio. Morgan Stanley has "Equal-Weight" rating and $6 target. Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. Barclays upped their target price on shares of Abbott Laboratories from $66.00 to $70.00 and gave the company an "overweight" rating in a research note on Thursday, January 25th. They expect $0.58 earnings per share, up 20.83% or $0.10 from last year's $0.48 per share. CRM's profit will be $124.51 million for 176.28 P/E if the $0.17 EPS becomes a reality. The insider Reynolds Shelley sold $795,502. $18.50 million worth of Amazon.com, Inc. Heritage Trust Co now owns 2,175 shares of the healthcare product maker's stock valued at $106,000 after purchasing an additional 200 shares during the period. BIRD ROGER sold $518,450 worth of stock. HAP Trading LLC increased its holdings in shares of Abbott Laboratories by 5.8% in the 2nd quarter.

Investors sentiment increased to 1.29 in 2017 Q4. Its up 0.03, from 1.26 in 2017Q3. 297 shares were sold by Watkin Jared, worth $17,609. 168 funds opened positions while 667 raised stakes. (NYSE:CRM). Allen Invest Mngmt Lc has invested 0.05% in salesforce.com, inc. Dowling And Yahnke Limited Liability reported 26,822 shares stake. Moreover, Mai has 0.03% invested in salesforce.com, inc. (NASDAQ:AMZN). Veritas Investment Mgmt (Uk) owns 168 shares. Alliancebernstein Lp invested in 0.51% or 12.46M shs. Adage Capital Prtn Group Lc holds 1.57% or 594,583 shares.